Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 2/10

vs
industry
vs
history
Cash-to-Debt 0.10
MACK's Cash-to-Debt is ranked lower than
97% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 54.02 vs. MACK: 0.10 )
Ranked among companies with meaningful Cash-to-Debt only.
MACK' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.1  Med: 2.07 Max: 1051.13
Current: 0.1
0.1
1051.13
Equity-to-Asset -3.08
MACK's Equity-to-Asset is ranked lower than
98% of the 709 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. MACK: -3.08 )
Ranked among companies with meaningful Equity-to-Asset only.
MACK' s Equity-to-Asset Range Over the Past 10 Years
Min: -3.82  Med: -1.55 Max: -0.04
Current: -3.08
-3.82
-0.04
Piotroski F-Score: 3
Altman Z-Score: -18.81
Beneish M-Score: -0.29
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -76.34
MACK's Operating Margin % is ranked higher than
52% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -92.31 vs. MACK: -76.34 )
Ranked among companies with meaningful Operating Margin % only.
MACK' s Operating Margin % Range Over the Past 10 Years
Min: -2220.11  Med: -212.97 Max: -64.48
Current: -76.34
-2220.11
-64.48
Net Margin % -105.18
MACK's Net Margin % is ranked lower than
53% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -79.00 vs. MACK: -105.18 )
Ranked among companies with meaningful Net Margin % only.
MACK' s Net Margin % Range Over the Past 10 Years
Min: -2284.59  Med: -209.06 Max: -81.06
Current: -105.18
-2284.59
-81.06
ROA % -97.55
MACK's ROA % is ranked lower than
85% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: -29.87 vs. MACK: -97.55 )
Ranked among companies with meaningful ROA % only.
MACK' s ROA % Range Over the Past 10 Years
Min: -110.9  Med: -75.96 Max: -47.47
Current: -97.55
-110.9
-47.47
ROC (Joel Greenblatt) % -574.16
MACK's ROC (Joel Greenblatt) % is ranked lower than
54% of the 907 Companies
in the Global Biotechnology industry.

( Industry Median: -394.49 vs. MACK: -574.16 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
MACK' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1458.87  Med: -719.41 Max: -468.88
Current: -574.16
-1458.87
-468.88
3-Year Revenue Growth Rate 33.60
MACK's 3-Year Revenue Growth Rate is ranked higher than
81% of the 507 Companies
in the Global Biotechnology industry.

( Industry Median: 5.10 vs. MACK: 33.60 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
MACK' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -31.2 Max: 33.6
Current: 33.6
0
33.6
3-Year EBITDA Growth Rate -11.30
MACK's 3-Year EBITDA Growth Rate is ranked lower than
64% of the 534 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. MACK: -11.30 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
MACK' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -32.8 Max: -2.4
Current: -11.3
3-Year EPS without NRI Growth Rate -2.90
MACK's 3-Year EPS without NRI Growth Rate is ranked higher than
50% of the 519 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. MACK: -2.90 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
MACK' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -38.1 Max: 1.3
Current: -2.9
0
1.3
GuruFocus has detected 6 Warning Signs with Merrimack Pharmaceuticals Inc $MACK.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» MACK's 10-Y Financials

Financials (Next Earnings Date: 2017-06-01 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

MACK Guru Trades in Q1 2016

Paul Tudor Jones 17,800 sh (New)
Jim Simons 636,613 sh (New)
Murray Stahl 25,000 sh (unchged)
» More
Q2 2016

MACK Guru Trades in Q2 2016

Jim Simons 744,813 sh (+17.00%)
Murray Stahl 25,000 sh (unchged)
Paul Tudor Jones 11,400 sh (-35.96%)
» More
Q3 2016

MACK Guru Trades in Q3 2016

Murray Stahl 25,000 sh (unchged)
Paul Tudor Jones Sold Out
Jim Simons Sold Out
» More
Q4 2016

MACK Guru Trades in Q4 2016

Paul Tudor Jones 45,209 sh (New)
Murray Stahl 25,000 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with MACK

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:CALA, NAS:BLCM, NAS:MYOK, NAS:CRBP, NAS:AVDL, NAS:CRIS, OTCPK:ZLDPF, OTCPK:ABVC, NAS:BSTC, NAS:NSTG, AMEX:BTX, NAS:BYSI, NAS:CNCE, NAS:CRVS, NAS:PDLI, NAS:MRUS, NAS:ASMB, NAS:BOLD, NAS:SYRS, NAS:AGEN » details
Traded in other countries:MP6.Germany,
Headquarter Location:USA
Merrimack Pharmaceuticals Inc is engaged in discovering, developing and preparing to commercialize medicines consisting of novel therapeutics paired with companion diagnostics for the treatment of cancer.

Merrimack Pharmaceuticals is a biotechnology company that discovers, develops, and commercializes innovative medicines that consist of novel therapeutics paired with diagnostics to treat cancer. The company's core approach to systems biology is to apply multidisciplinary capabilities to build functional and predictive computational models of biological systems, such as cell signaling networks. Merrimack also enters into third-party agreements to further process and commercialize its products.

Ratios

vs
industry
vs
history
PS Ratio 2.70
MACK's PS Ratio is ranked higher than
83% of the 685 Companies
in the Global Biotechnology industry.

( Industry Median: 12.47 vs. MACK: 2.70 )
Ranked among companies with meaningful PS Ratio only.
MACK' s PS Ratio Range Over the Past 10 Years
Min: 1.78  Med: 8.6 Max: 16.67
Current: 2.7
1.78
16.67
EV-to-EBIT -5.42
MACK's EV-to-EBIT is ranked lower than
99.99% of the 423 Companies
in the Global Biotechnology industry.

( Industry Median: 22.87 vs. MACK: -5.42 )
Ranked among companies with meaningful EV-to-EBIT only.
MACK' s EV-to-EBIT Range Over the Past 10 Years
Min: -20.4  Med: -6.6 Max: -0.5
Current: -5.42
-20.4
-0.5
EV-to-EBITDA -5.75
MACK's EV-to-EBITDA is ranked lower than
99.99% of the 466 Companies
in the Global Biotechnology industry.

( Industry Median: 17.12 vs. MACK: -5.75 )
Ranked among companies with meaningful EV-to-EBITDA only.
MACK' s EV-to-EBITDA Range Over the Past 10 Years
Min: -21.4  Med: -6.8 Max: -0.5
Current: -5.75
-21.4
-0.5
Current Ratio 0.65
MACK's Current Ratio is ranked lower than
92% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 4.05 vs. MACK: 0.65 )
Ranked among companies with meaningful Current Ratio only.
MACK' s Current Ratio Range Over the Past 10 Years
Min: 0.65  Med: 2.08 Max: 3.33
Current: 0.65
0.65
3.33
Quick Ratio 0.49
MACK's Quick Ratio is ranked lower than
93% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. MACK: 0.49 )
Ranked among companies with meaningful Quick Ratio only.
MACK' s Quick Ratio Range Over the Past 10 Years
Min: 0.49  Med: 2.07 Max: 3.33
Current: 0.49
0.49
3.33
Days Inventory 564.45
MACK's Days Inventory is ranked lower than
96% of the 436 Companies
in the Global Biotechnology industry.

( Industry Median: 126.28 vs. MACK: 564.45 )
Ranked among companies with meaningful Days Inventory only.
MACK' s Days Inventory Range Over the Past 10 Years
Min: 482.42  Med: 7614.61 Max: 14746.79
Current: 564.45
482.42
14746.79
Days Sales Outstanding 44.20
MACK's Days Sales Outstanding is ranked higher than
65% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 61.11 vs. MACK: 44.20 )
Ranked among companies with meaningful Days Sales Outstanding only.
MACK' s Days Sales Outstanding Range Over the Past 10 Years
Min: 11.77  Med: 56.03 Max: 300.77
Current: 44.2
11.77
300.77
Days Payable 178.70
MACK's Days Payable is ranked higher than
81% of the 409 Companies
in the Global Biotechnology industry.

( Industry Median: 58.37 vs. MACK: 178.70 )
Ranked among companies with meaningful Days Payable only.
MACK' s Days Payable Range Over the Past 10 Years
Min: 9.02  Med: 100.35 Max: 40062.72
Current: 178.7
9.02
40062.72

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -8.30
MACK's 3-Year Average Share Buyback Ratio is ranked higher than
60% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: -11.10 vs. MACK: -8.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
MACK' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -111.1  Med: -8.3 Max: 0
Current: -8.3
-111.1
0

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 0.31
MACK's Price-to-Median-PS-Value is ranked higher than
88% of the 584 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. MACK: 0.31 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
MACK' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.31  Med: 1.13 Max: 1.33
Current: 0.31
0.31
1.33
Earnings Yield (Greenblatt) % -18.45
MACK's Earnings Yield (Greenblatt) % is ranked lower than
74% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: -6.37 vs. MACK: -18.45 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
MACK' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -5065.97  Med: 0 Max: 0
Current: -18.45
-5065.97
0

More Statistics

Revenue (TTM) (Mil) $144.3
EPS (TTM) $ -1.21
Beta2.40
Short Percentage of Float23.27%
52-Week Range $2.83 - 7.74
Shares Outstanding (Mil)130.57

Analyst Estimate

Dec17 Dec18
Revenue (Mil $) 202 316
EPS ($) -0.93 -0.42
EPS without NRI ($) -0.93 -0.42
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for MACK

Headlines

Articles On GuruFocus.com
Merrimack Appoints Daryl Drummond, Ph.D. as Head of Research Apr 17 2017 
Merrimack Declares $140M Special Dividend in Connection with Recently Completed Asset Sale Apr 05 2017 
Merrimack Launches as New, Refocused Research & Clinical Development Company with Resources to Advan Apr 03 2017 
Merrimack Stockholders Approve Sale of ONIVYDE® and Generic Version of DOXIL® to Ipsen for Up Mar 31 2017 
Weekly CEO Sells Highlight: Starbucks Corp, KD Supply Holdings Inc, Capital One Financial Corp, Merr Dec 14 2014 

More From Other Websites
Merrimack Pharmaceuticals, Inc. – Value Analysis (NASDAQ:MACK) : April 19, 2017 Apr 19 2017
Merrimack Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : MACK-US :... Apr 18 2017
Merrimack Appoints Daryl Drummond, Ph.D. as Head of Research Apr 17 2017
Merrimack Declares $140M Special Dividend in Connection with Recently Completed Asset Sale Apr 05 2017
Merrimack Launches as New, Refocused Research & Clinical Development Company with Resources to... Apr 03 2017
Are Options Traders Betting on a Big Move in Merrimack (MACK) Stock? Mar 31 2017
Merrimack Stockholders Approve Sale of ONIVYDE® and Generic Version of DOXIL® to Ipsen for Up to... Mar 30 2017
Merrimack to Present at the 2017 American Association for Cancer Research Annual Meeting Mar 27 2017
Merrimack (MACK) Starts Enrollment in Solid Tumors Study Mar 24 2017
​Merrimack asset sale prompts legal blowback Mar 23 2017
Merrimack Initiates Phase 1 Study of MM-310 in Solid Tumors Mar 23 2017
Lawyer: former Merrimack employee accused of insider trading to fight charges Mar 22 2017
Merrimack Pharmaceuticals, Inc. :MACK-US: Earnings Analysis: Q4, 2016 By the Numbers : March 15,... Mar 15 2017
Biotech's Fall as President Trump to Address Pricing Concerns: Today's Research Reports on Arena... Mar 08 2017
Merrimack (MACK) Q4 Loss Lower than Expected, Revenues Top Mar 02 2017
These 5 Stocks Under $10 Could Explode Up Soon Mar 02 2017
Edited Transcript of MACK earnings conference call or presentation 1-Mar-17 1:30pm GMT Mar 01 2017
Merrimack's (MACK) Q4 Loss In-Line With Estimates Mar 01 2017
Merrimack reports 4Q loss Mar 01 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)